Discovery of pyrrolopyrimidinone inhibitors of the BCL6-SMRT corepressor interaction

Key Points

• Pyrrolopyrimidinone inhibitors effectively disrupt the BCL6-SMRT corepressor interaction.
• The binding affinity shows a significant decrease of 60% in the presence of these inhibitors.
• Molecular docking simulations reveal interaction mechanisms for the inhibitors with the BCL6-SMRT complex.
• Further exploration may lead to new cancer treatments targeting this interaction.